TRIO Pharmaceuticals, a San Diego, CA-based biotechnology company pioneering bispecific antibodies for the treatment of cancer, raised $3.1M in funding.
The round was led by Friedman Bioventure Fund (FBVF). Other investors included Multiple Myeloma Research Foundation (MMRF), through its venture philanthropy arm, the Myeloma Investment Fund (MIF).
The company intends to use the funds to accelerate its journey towards clinical trials.
Led by CEO Dr. Reiner Laus, Trio Pharmaceuticals is a cancer immunotherapeutics company developing bispecific antibodies for the treatment of cancer with potency and selectivity. Its antibody drugs directly stop tumor growth without affecting normal cells and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways.
The company is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells.
